Evaluation of primary in haemostatis in people with neurofibromatosis type 1

Clinical and Laboratory Haematology

Volumn 26, Issue 5, 2004, Pages 341-345

  Favaloro, E J ^a   Zafer, M ^a   Nair, S C ^a   Hertzberg, M ^a   North, K ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Neurofibromatosis 1; PFA 100; Platelet function; Primary haemostasis; Von Willebrand factor; VWF; VWF: Ag; VWF: CB

Indexed keywords

BLOOD CLOTTING FACTOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; NEUROFIBROMATOSIS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; SCHOOL CHILD; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; BLEEDING; BLOOD; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD EXAMINATION; CHILD; MIDDLE AGED; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHILD; FEMALE; HEMATOLOGIC TESTS; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; PLATELET FUNCTION TESTS; REGRESSION ANALYSIS; VON WILLEBRAND FACTOR;

EID: 7444247940     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2004.00632.x     Document Type: Article

References (19)

1. Ademiluyi S.A., Sowemimo G.O.A. & Oyeneyin J.O. (1989) Surgical experience in the management of multiple neurofibromatosis in Nigerians. West African Journal of Medicine 8, 59-65.
2. Favaloro E.J. (2000) Collagen binding assay for von Willebrand Factor (VWF:CBA): detection of von Willebrand's disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thrombosis & Haemostasis 83, 127-135.
3. Favaloro E.J. (2001) Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 7, 170-179.
4. Favaloro E.J. (2002) Clinical utility of the PFA-100®. Current Opinions in Haematology 9, 407-415.
5. Favaloro E.J., Grispo L., Exner T. & Koutts J. (1991) Development of a simple collagen-based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagulation and Fibrinolysis 2, 285-291.
6. Favaloro E.J., Kershaw G., Bukuya M., Hertzberg M. & Koutts J. (2001) Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: Efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies. Haemophilia 7, 180-189.
7. Garcia V.V., Alberca I., Prieto J. & Borrasca A.L. (1982) Von Willebrand's syndrome associated with von Recklinghausen neurofibromatosis. Blut 45, 417-418.
8. Giorno R., Lieber J. & Claman H.N. (1989) Ultrastructural evidence for mast cell activation in a case of neurofibromatosis. Neurofibromatosis 2, 35-41.
9. Harrison P., Robinson M., Liesner R., Khair K., Cohen H., Mackie I. & Machin S. (2002) The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clinical Laboratory Haematology 24, 225-232.
10. Huson S.M., Harper P.S. & Compston D.A.S. (1988) von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales. Brain 111, 1355-1381.
11. Mohammed A., Mehrabani P.A., Coombs R., Molesworth L. & Favaloro E.J. (1997) The MDA-180 Coagulation Analyser: a laboratory evaluation. Pathology 29, 176-183.
12. National Institutes of Health, Consensus Development Conference (1988) Neuofibromatosis Conference Statement, 1987. Archives of Neurology 45, 575-578.
13. North, K.N. (1993) Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. Journal of Child Neurology 8, 395-403.
14. Prieto Veiga J., Cedeno M.J., de Maueles J.J., Vicente G.V., Alberca S.I. & Salazar V.V. (1983) The pathology of factor VIII in von Recklinghausen's disease: a new association. Anales Espanales de Pediatria 19, 303-307.
15. Rasko J.E.J., North K., Favaloro E.J., Grispo L. & Berndt M.C. (1995) Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1. British Journal of Haematology 89, 582-588.
16. Riccardi V.M. (1981) Cutaneous manifestations of neurofibromatosis: cellular interaction, pigmentation and mast cells. Birth Defects 17, 129-145.
17. Riccardi V.M. (1992) Neurofibromatosis: Phenotype, Natural History and Pathogenesis. Johns Hopkins University Press, Baltimore, MD.
18. Sadler J.E., Mannucci P.M., Berntorp E., Bochkov N., Boulyjenkov V., Ginsberg D., Meyer D., Peake I., Rodeghiero F. & Srivastava A. (2000) Impact, diagnosis and treatment of von Willebrand Disease. Thrombosis & Haemostasis 84, 160-174.
19. Weber K. & Braun-Falco O. (1972) Zur Ultrastruktur der Neurofibromatose. Hautarzt 23, 116-122.